Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof

A compound represented by the formula (I):

• wherein
• R1 is a hydrogen atom, C1-6 alkoxy, —OH, C1-6 alkyl or a halogen atom,
• X is —C(R5)═ or —N═,
• R5 is a hydrogen atom or C1-6 alkoxy,
• any one of R2, R3 and R4 is R6 and the remaining two are each a hydrogen atom,
• R6 is
• (1) —NR17—Y1—R7
• wherein Y1 is —C(═O)NR18—, —C(═S)NH—, —C(═NH)NH—, —C(═O)O—, —C(═O)—, —SO2— or —SO2—NR8—,
• R8 is a hydrogen atom or C1-6 alkyl,
• R17 is a hydrogen atom or C1-6 alkyl,
• R18 is a hydrogen atom or C1-6 alkyl, or
• R17 and R18 are optionally bonded to each other to form, together with the nitrogen atoms bonded thereto and adjacent C(═O), a 5- to 7-membered heterocycle,
• R7 is
• (a) C6-10 aryl,
• (b) 5- to 10-membered heteroaryl,
• (c) C1-6 alkyl, or
• (d) C2-6 alkenyl
• wherein C1-6 alkyl and C2-6 alkenyl are optionally substituted by one substituent selected from phenyl, furyl and diphenylmethylsulfinyl,
• C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted by optionally selected R9 in the number of 1 to 4,
• R9 are each independently
• a halogen atom,
• —NO2,
• —OH,
• C1-6 alkyl,
• C1-6 haloalkyl,
• C1-6 alkoxy,
• 5- to 10-membered heteroaryl,
• —NR9aR9b wherein R9a is a hydrogen atom, C1-6 alkyl or C1-6 alkoxy-carbonyl, and R9b is a hydrogen atom or C1-6 alkyl,
• —C(═O)OR9c wherein R9c is a hydrogen atom or C1-6 alkyl,
• —C(═O)NR9dR9e wherein R9d is a hydrogen atom or C1-6 alkyl, and R9e is a hydrogen atom or C1-6 alkyl, or
• —NH—C(═NR9f)—NHR9g wherein R9f is a hydrogen atom or C1-6 alkoxy-carbonyl, and R9g is a hydrogen atom or C1-6 alkoxy-carbonyl, or
• R9 in the number of 2 are joined to form methylenedioxy,
• (2) —NH—Y2—R10
• wherein Y2 is —CH2— or a single bond, and
• R10 is
• (a) C6-10 aryl, or
• (b) 5- to 10-membered heteroaryl
• wherein C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted by optionally selected R9 in the number of 1 to 4, and R9 is as defined above,
• (3) a group represented by the formula (ii):
• wherein R11 is C1-6 alkoxy or C6-10 arylamino (wherein C6-10 aryl moiety of the C6-10 arylamino is optionally substituted by 1 to 3 substituents selected from C1-6 alkyl and C1-6 alkoxy),
• (4) —N═N—R12
• wherein R12 is C6-10 aryl optionally substituted by 1 to 3 substituents selected from (a) C1-6 alkyl optionally substituted by —OH, (b) —OH, (c) di(C1-6 alkyl)amino and (d) C1-6 alkoxy-carbonylamino, or
• (5) —NR13R14
• wherein R13 is a hydrogen atom, C1-6 alkyl, C6-10 aryl-C1-6 alkyl or C2-6 alkenyl-carbonyl, and
• R14 is a hydrogen atom or C1-6 alkyl (wherein C1-6 alkyl is optionally substituted by one substituent selected from (a) C2-6 alkenyl-carbonylamino and (b) C6-10 aryl-C1-6 alkylaminocarbonyl optionally substituted by C1-6 alkyl), or R13 and R14 are bonded to each other to form, together with the nitrogen atom bonded thereto, a 5- to 7-membered heterocycle further containing one nitrogen atom (wherein 5- to 7-membered heterocycle is optionally substituted by C6-10 aryl-carbonyl optionally substituted by C1-6 alkyl),
• provided that when R14 is ethyl substituted by C2-6 alkenyl-carbonylamino, R13 is not a hydrogen atom, and
• W is
• a group represented by the formula (iii):
• wherein R15 is C1-6 alkyl, and R16 is C1-6 alkyl,
• or a pharmaceutically acceptable acid addition salt thereof.